Home > Journals > Panminerva Medica > Past Issues > Articles online first > Panminerva Medica 2020 Jul 22

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

 

Panminerva Medica 2020 Jul 22

DOI: 10.23736/S0031-0808.20.03912-9

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

Effect of interferon-α-2b and interleukin-2 combined with chemotherapy in metastatic melanoma

Zheng SU, Fen SHI, Jian ZHANG, Weiqiang LIANG

1 Department of Plastic and Reconstructive Surgery, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, China


PDF


BACKGROUND: To explore the efficacy and safety of interferon-α-2b and interleukin-2 combined with chemotherapy in treating patients with metastatic melanoma.
METHODS: The patients with metastatic melanoma in control group (n=52) were treated with conventional DDAVC chemotherapy regimen, while those in combination group (n=52) received biotherapy with interferon-α-2b and interleukin-2 in addition to the chemotherapy in control group. At the end of the treatments, the serum immune function indicators, short-term efficacy and incidence of adverse reactions were compared between the two groups of patients, and patient's survival was followed up and recorded.
RESULTS: At 1 week after treatment, it was found that the overall response rate in combination group was substantially higher than that in control group (P=0.027). Besides, according to the serologic test results at 1 week after the chemotherapy, T lymphocyte subset activity was enhanced in patients in combination group compared with that before chemotherapy, with no statistically significant difference (P>0.05), but it was notably weakened in control group in comparison with that before chemotherapy (P<0.05). Finally, it was discovered through the log-rank test that the overall survival (OS) rate in combination group was remarkably superior to that in control group (P=0.029), but there was no statistically significant difference in the progression-free survival (PFS) rate between the two groups (P=0.076).
CONCLUSIONS: Compared with chemotherapy alone, interferon-α-2b and interleukin-2 combined with chemotherapy can raise the clinical short-term efficacy and long-term OS rate in the patients with metastatic melanoma and alleviate their toxic side reactions, with higher safety.


KEY WORDS: Interferon-α-2b; Interleukin-2; Chemotherapy; Melanoma; Metastasis; Efficacy

top of page